Health News and Scoops

Delcath and Ohio State have entered into a clinical research agreement to conduct the Phase III National Cancer Institute (NCI) led study. Dr. Mark Bloomston, a surgical oncologist specializing in regional cancer therapy, will serve as the Principal Investigator.

Commenting on joining this trial, Dr. Bloomston stated, “The Delcath PHP System is a welcome addition to the currently available therapies for liver cancer, and we look forward to treating patients in this trial. Metastatic melanoma, once it reaches the liver, has few viable treatment options.

This technology offers a very promising approach for targeting the disease in the liver and we are eager to provide this modality to our patients.”

Commenting on this twelfth center joining the trial, Richard L. Taney, President and CEO of Delcath, stated, “We are delighted to have Ohio State and Dr. Bloomston join this trial as we continue to expand to an increasing number of leading cancer centers in the United States. The prestige of these centers is a validation of the need for a viable treatment option for these very ill patients.

Continuing to expand this trial assists in the acceleration of enrollment, increases the awareness of the Delcath PHP System among physicians, and expands patient access to PHP.”

(Source) Press

Singapore is flexing muscles in cancer research seemingly all out of proportion to its size. The country has carved a niche for itself by focusing research on select cancers, as well as offering patients of advanced cancer the possibility of targeted therapies

A new clinical trial is now underway and outcomes are expected to have far-reaching implications for both doctors and their patients.

The trial is considered groundbreaking for several reasons, not least because it uses the patient’s own immune system to fight the cancer. Helmed by Dr Toh Han Chong, Head of Department of Medical Oncology at the National Cancer Centre in Singapore (NCCS), the study currently involves 38 patients. The NCCS is a multi-disciplinary centre that offers one-stop cancer diagnosis and treatment, and carries out cutting-edge cancer research.

Read